Annals of Allergy Asthma & Immunology, Journal Year: 2022, Volume and Issue: 130(3), P. 355 - 358
Published: Dec. 10, 2022
Language: Английский
Allergy, Journal Year: 2022, Volume and Issue: 78(2), P. 369 - 388
Published: Nov. 24, 2022
Abstract There has been an important change in the clinical characteristics and immune profile of Coronavirus disease 2019 (COVID‐19) patients during pandemic thanks to extensive vaccination programs. Here, we highlight recent studies on COVID‐19, from immunological protective risk factors for severity mortality COVID‐19. The efficacy COVID‐19 vaccines potential allergic reactions after administration are also discussed. occurrence new variants concerns such as Omicron BA.2, BA.4, BA.5 global have changed scenario Multisystem inflammatory syndrome children (MIS‐C) may cause severe heterogeneous but with a lower rate. Perturbations immunity T cells, B mast well autoantibodies metabolic reprogramming contribute long‐term symptoms is conflicting evidence about whether atopic diseases, asthma rhinitis, associated susceptibility better outcomes At beginning pandemic, European Academy Allergy Clinical Immunology (EAACI) developed guidelines that provided timely information management diseases preventive measures reduce transmission clinics. distribution emerging acute respiratory coronavirus 2 (SARS‐CoV‐2) reduced pathogenic dramatically decreased morbidity, severity, Nevertheless, breakthrough infection remains challenge control. Hypersensitivity (HSR) low compared other vaccines, these were addressed EAACI statements indications reactions, including anaphylaxis vaccines. We gained depth knowledge experience over years since start yet full eradication SARS‐CoV‐2 not horizon. Novel strategies warranted prevent high‐risk groups, development MIS‐C long
Language: Английский
Citations
76
Annals of Allergy Asthma & Immunology, Journal Year: 2024, Volume and Issue: 133(3), P. 286 - 294
Published: June 5, 2024
Language: Английский
Citations
7
Frontiers in Pharmacology, Journal Year: 2022, Volume and Issue: 13
Published: Oct. 3, 2022
Background: Dupilumab is a human monoclonal antibody directed against the alpha subunit of interleukin-4 receptor and inhibits signaling IL-4 IL-13. It approved for treating asthma other type-2 inflammatory diseases. There conflict in literature regarding safety efficacy dupilumab. Thus, we aimed to assess dupilumab patients with moderate severe asthma. Methods: Six databases (PubMed, Embase, Scopus, Web Science, Cochrane library, clinicaltrials.gov registry) were searched until January 2022. We included randomized controlled trials that compared placebo patients. extracted data at 12 24 weeks analyzed them using review manager 5.4. Findings: Thirteen included. significantly improved forced expiratory volume 1 s, control questionnaire score, fraction exhaled nitric oxide level, immunoglobulin E level ( p < 0.05). However, it was associated increased blood eosinophils weeks. generally safe agent asthmatic showed no significant difference most adverse events. Conclusion: improves pulmonary function reduces local systemic markers minimal events
Language: Английский
Citations
12
American Journal of Respiratory and Critical Care Medicine, Journal Year: 2022, Volume and Issue: 206(6), P. 780 - 783
Published: June 1, 2022
Language: Английский
Citations
8
Journal of Leukocyte Biology, Journal Year: 2024, Volume and Issue: unknown
Published: Jan. 30, 2024
Abstract Eosinophils are a critical type of immune cell and central players in 2 immunity. Existing literature suggests that eosinophils also can play role host antiviral responses, typically 1 events, against multiple respiratory viruses, both directly through release mediators indirectly activation other effector types. One way to prime responses toward effective is vaccination, where 1–skewed immunity desirable the context intracellular pathogens like viruses. In realm breakthrough viral infection vaccinated hosts, an event which virus still establish productive despite preexisting immunity, most prominently known for their link vaccine-associated enhanced disease upon natural syncytial infection. This was observed pediatric cohort during 1960s following vaccination with formalin-inactivated virus. More recent research has unveiled additional roles eosinophil The specific contribution quality vaccine efficacy, hosts remains largely unexplored, especially regarding potential protection. On basis current findings, we will speculate suggested function consider many ways by may exert protective pathological effects infections. We discuss how balance efficacy eosinophil-related risks, as well use products biomarkers or adverse events.
Language: Английский
Citations
1
Authorea (Authorea), Journal Year: 2022, Volume and Issue: unknown
Published: Aug. 22, 2022
There has been an important change in the clinical characteristics and immune profile of COVID-19 patients during pandemic thanks to extensive vaccination programs. Here, we highlight recent studies on COVID-19, from immunological protective risk factors for severity mortality COVID-19. The efficacy vaccines potential allergic reactions after administration are also discussed. occurrence new variants concerns such as Omicron BA.2, BA.4 BA.5 global have changed scenario Multisystem inflammatory syndrome children (MIS-C) identified cause death with Perturbations immunity T cells, B mast well autoantibodies metabolic reprogramming may contribute long-term symptoms Atopic diseases, asthma rhinitis, shown be associated a lower susceptibility better outcomes At beginning pandemic, EAACI developed guidelines that provided timely information management diseases preventive measures reduce transmission clinics. distribution emerging SARS-CoV-2 reduced pathogenic dramatically decreased morbidity, severity, Nevertheless, breakthrough infection remains challenge disease control. Hypersensitivity (HSR) low compared other vaccines, these were addressed statements indications reactions, including anaphylaxis vaccines. We gained depth knowledge experience over 2 years since start yet full eradication is not horizon. Novel strategies warranted prevent severe high-risk groups, development MIS-C long COVID.
Language: Английский
Citations
4
Allergy, Journal Year: 2022, Volume and Issue: 78(2), P. 571 - 574
Published: Oct. 1, 2022
Studies on the pathophysiology of immune responses in COVID-19 point at a critical role for Th1 cells viral clearance. Therefore, it has been postulated that abnormally elevated Th2 cytokines individuals with atopic dermatitis (AD), dermatological condition characterized by Th2-driven skin inflammation, impairs appropriate to infection and specific Th2-targeting therapies are corrective.1 In line this hypothesis, we previously showed dupilumab, monoclonal antibody blocks IL-4Rα subunit, thereby inhibiting Th2-associated IL-4 IL-13 signaling, is associated milder severity AD patients.1 Importantly, dupilumab does not affect SARS-CoV-2 IgG levels after vaccination.2 However, effect T cell or vaccination known. We prospectively collected PMBC samples from ≥12 year old moderate-to-severe patients either mRNA Department Dermatology Icahn School Medicine, New York, between June 2020 October 2021. Fifty-five prior confirmed positive anti-SARS-CoV-2 Spike (unvaccinated time sample collection), 125 post-vaccination different subjects were analyzed. PBMCs incubated 24 h peptides covering immune-dominant regions S glycoprotein IFNγ IL-2 antigen-specific quantified using IFNγ/IL-2 Double-Color FluoroSpot (see Methods S1 Figure further details). antigens used provide comparisons treatment groups as measure both post-infection (the vaccine contains only spike antigen SARS-CoV-2). Comparisons log10-transformed spot counts minimize impact outliers made unpaired Student's t-tests correlations calculated Spearman correlation coefficient. Patients stratified into three cohorts based their strategy: (1) Dupilumab alone (Dupilumab); (2) other systemics immunomodulators (JAK-inhibitors, prednisone, phototherapy; Systemic), (3) untreated topical medications (Limited). After infection, IFNγ+ cell-reactive non-significantly higher (n = 24) vs. Limited 23) (p .072 [FDR 0.144]; 1A). IL-2+ dual IFNγ+IL-2+ did differ these two (not shown), but IFNγ+/IL-2+ count ratio trended toward an increase .091 0.182]; 1B). No differences identified Systemics 8) terms ratio. samples, there significantly greater .048 0.071]; 2A) trend .068 0.068]; 2A). The was .181 0.362]; 2B) Systemics. observed no vaccination, consistent previous reports.3 To validate results, subset patients, determined specificity memory (CD45RA−) IL-2- IFNγ-producing CD4+ flow cytometry CD154 (CD40L) early activation marker upregulated upon recognition. While significant CD154+IL-2+ groups, percentage Spike-specific (CD154+ IFNγ+) dupilumab-treated group (Figure S2A,B). Consistent studies,4 augmentation treated Dupilumab. This study supports hypothesis promotes more balanced Th1/Th2 response (as shown comparison group, consisting receiving systemic treatments), trends increased SARS-CoV-2-specific ratio, potentially indicator given IL-2's involvement multiple Th pathways.5 Furthermore, blunting abnormal activity cells, appears promote Th1-prone vaccination. Of note, than across all treatments. Further work necessary evaluate this, raising question whether protein presence may elicit robust Limitations include small size, unknown dates (prior serologies), lack serial samples. Future studies larger populations needed characterize phenotypes thoroughly. Overall, suggests Th2-inhibition hinder, possibly even improve, Th1-specific thank Mount Sinai Biorepository & Pathology Core providing support processing. supported Medicine grant Regeneron Sanofi. recruited within Medicine. All funding sources reviewed accepted design manuscript, minimal input Research reported publication also National Institute Allergy Infectious Diseases Institutes Health under Award Number U01AI152036. content solely responsibility authors necessarily represent official views Health. Paolo Cravedi 3U01AI063594-17S1. E. Guttman-Yassky employee received research funds (grants paid institution) Abbvie, Amgen, AnaptysBio, AstraZeneca, Boehringer-Ingelhiem, Cara Therapeutics, Innovaderm, Janssen, KAO, Kyowa Kirin, Leo Pharma, Pfizer, Pharmaceuticals, Inc., UCB; consultant Almirall, Arena, Asana Biosciences, Boehringer-Ingelheim, Bristol-Meyers Squibb, Connect Eli Lilly, EMD Serono, Evidera, Galderma, Ichnos Sciences, Incyte, Janssen Biotech, Pandion Ribon, RAPT Sanofi, SATO Pharmaceutical, Siolta Target PharmaSolutions, UCB, Ventyx Biosciences. B. Ungar from: Rapt Pfizer. He Arcutis Biotherapeutics Castle A. Golant Is served speaker Regeneron, Dermavant, LEO Evelo Pavel conducts sponsored Regeneron. have conflicts interest disclose. Appendix Please note: publisher responsible functionality any supporting information supplied authors. Any queries (other missing content) should be directed corresponding author article.
Language: Английский
Citations
4
Global Health & Medicine, Journal Year: 2023, Volume and Issue: 5(6), P. 366 - 371
Published: Nov. 14, 2023
Immunocompromised coronavirus disease 2019 patients are at a higher risk of prolonged viral shedding than immunocompetent patients. However, as August 2023, there is no clear international standard for de-isolating vulnerable A comprehensive assessment advisable based on various information, such the increase in immune escape specific mutant strains well patient's innate immunity and vaccination status; therefore, consultation with an infectious specialist recommended. The patient population defined moderately or severely immunocompromised by Centers Disease Control Prevention European Centre significantly broad. boundary between two remains to be delineated, existing protocols allow release their symptoms alone. This may lead unnecessary extension premature termination isolation. In this study, we searched studies, particularly those that used real-world data, discussed results experts our hospital, proposed new isolation criteria both testing clinical symptoms. We classified into three groups namely severely, moderately, mildly immunocompromised, background administration immunosuppressive drugs. separate flowchart ending indicated each group. useful support material, especially non-specialists. Nevertheless, must revised added continuously; accumulating data revision addition list becoming increasingly important.
Language: Английский
Citations
1
Journal of Allergy and Clinical Immunology Global, Journal Year: 2023, Volume and Issue: 3(1), P. 100181 - 100181
Published: Oct. 18, 2023
The coronavirus disease 2019 (COVID-19) pandemic caused significant disruptions to health care services and impacts on patients with atopic dermatitis (AD) and/or food allergy (FA).We evaluated the impact of COVID-19 AD/FA patients.A comprehensive systematic literature search was conducted from December 2022. Screening data extraction were done following Preferred Reporting Items for Systematic Reviews Meta-analysis (PRISMA) guidelines, Mixed Methods Appraisal Tool, or MMAT, used assess risk bias.In total, 159 studies included. Five 7 reported no changes in overall incidence prevalence AD during pandemic, although some noted an increase elderly infants. Telehealth served as effective alternative face-to-face consultations, mixed levels patient provider satisfaction. Dissatisfaction most marked more severe disease, who thought that their inadequately managed through telemedicine. Higher general anxiety recorded both caregivers, it pronounced disease. Most differences postvaccination adverse effects patients; however, results varied FA patients.Our review identified pandemic- disease-driven patients. Telemedicine is uniquely suited manage diseases, hybrid may be a suitable approach even postpandemic era. vaccines biologics can safely administered appropriate education ensure continued high-risk
Language: Английский
Citations
1
Journal of Dermatological Treatment, Journal Year: 2022, Volume and Issue: 33(7), P. 3066 - 3067
Published: June 20, 2022
"Letter to the editor submitted in response ‘Incidence and prognosis of COVID-19 patients with atopic diseases on dupilumab: a multicentre retrospective cohort study’." Journal Dermatological Treatment, ahead-of-print(ahead-of-print), pp. 1–2
Language: Английский
Citations
0